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Abstract
Background: Suicide is the consequence of a complex set of factors that results in devastation for a staggering
number of people. Worldwide, suicide is responsible for over 800 000 deaths annually, while many more
millions of survivors are left to cope with the repercussions of this tragedy. Despite the rampant prevalence
and dire consequences, the medical community has yet to successfully establish an effective way for clinicians
to anticipate a suicide attempt. However, researchers have recently identified several genes that appear altered
in both suicide completers and patients suffering from suicidal ideation. These genes can be measured via
RNA extraction from a sample of blood. The implications of this research are significant, for if a blood test can
aid in the predication of suicide risk, clinicians may have a feasible tool to assist in the prevention of millions
of deaths.
Methods: An exhaustive search of available medical literature was conducted using Medline-OVID,
PsychINFO, and Web of Science using the keywords: suicide, SAT1, and acetyltransferase. The search was
narrowed to include only English language and human study articles. The bibliographies of the articles were
further searched for relevant sources. Articles with primary data evaluating SAT1 gene expression in subjects
who completed suicide or experienced suicidal ideation were included.
Results: Four studies were ultimately included in this systematic review. All four studies demonstrated
significantly altered levels of SAT1 gene expression in suicide victims compared to controls. Additionally, a
cohort study demonstrated increased SAT1 gene expression in live patients reporting severe suicidal ideation.
These authors further determined that live patients with increased SAT1 gene expression have increased rates
of hospitalizations resulting from a suicide attempt.
Conclusion: Dysregulation of SAT1 gene expression appears to be associated with suicidal behavior, though
it remains unknown why this link exists and the quality of available data is very low. At this time, applications
for clinical practice are minimal. However, additional research is highly warranted, as these preliminary
findings suggest that SAT1 gene expression may indeed act as a biomarker and could someday aid in the
prediction of a patient’s susceptibility for suicide.
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Abstract 
 
Background: Suicide is the consequence of a complex set of factors that results in 
devastation for a staggering number of people. Worldwide, suicide is responsible for over 
800 000 deaths annually, while many more millions of survivors are left to cope with the 
repercussions of this tragedy. Despite the rampant prevalence and dire consequences, the 
medical community has yet to successfully establish an effective way for clinicians to 
anticipate a suicide attempt. However, researchers have recently identified several genes 
that appear altered in both suicide completers and patients suffering from suicidal 
ideation. These genes can be measured via RNA extraction from a sample of blood. The 
implications of this research are significant, for if a blood test can aid in the predication 
of suicide risk, clinicians may have a feasible tool to assist in the prevention of millions 
of deaths.  
 
Methods: An exhaustive search of available medical literature was conducted using 
Medline-OVID, PsychINFO, and Web of Science using the keywords: suicide, SAT1, 
and acetyltransferase. The search was narrowed to include only English language and 
human study articles.  The bibliographies of the articles were further searched for 
relevant sources.  Articles with primary data evaluating SAT1 gene expression in subjects 
who completed suicide or experienced suicidal ideation were included. 
 
Results:  Four studies were ultimately included in this systematic review. All four studies 
demonstrated significantly altered levels of SAT1 gene expression in suicide victims 
compared to controls. Additionally, a cohort study demonstrated increased SAT1 gene 
expression in live patients reporting severe suicidal ideation. These authors further 
determined that live patients with increased SAT1 gene expression have increased rates 
of hospitalizations resulting from a suicide attempt.  
 
Conclusion:  Dysregulation of SAT1 gene expression appears to be associated with 
suicidal behavior, though it remains unknown why this link exists and the quality of 
available data is very low. At this time, applications for clinical practice are minimal. 
However, additional research is highly warranted, as these preliminary findings suggest 
that SAT1 gene expression may indeed act as a biomarker and could someday aid in the 
prediction of a patient’s susceptibility for suicide.  
 
Keywords:  Suicide, SAT1 gene
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Identification of the SAT1 Gene as a Potential 
Biomarker for the Prediction of Suicide in Patients 
Suffering from Mood Disorders  
BACKGROUND 
 
Suicide is the tragic consequence of a complex set of factors that results in 
devastation for a staggering number of people. Suicide is the tenth leading cause of death 
in America, with 40 600 suicides reported in 2012.1 Worldwide, suicide is responsible for 
over 800 000 deaths annually. In young patients aged 15-29 years, it is the third leading 
cause of death globally, and after cancer and heart disease, accounts for more premature 
deaths than any other disease.2 These numbers fail to capture the other victims of suicide: 
the many millions of survivors, including families, friends, and communities that are left 
to cope with the horrifying repercussions of this tragedy.  
Despite the rampant prevalence and dire consequences, the medical community 
has yet to successfully establish an effective way for clinicians to anticipate a suicide 
attempt. A suicidal crisis results from the culmination of several complex subjective 
factors, including environment, personality, interpretation and reaction to acute and 
chronic stressors, substance abuse, portrayal of suicide in the media, personal history of 
suicidal ideation (SI) or attempt, family history of suicide, and access to a means.3,4 
Because these subjective contributors to a suicidal state cannot be evaluated or quantified 
in a way that confirms intent, clinicians are at an overwhelming disadvantage when 
assessing a patient for suicide risk. Furthermore, patients contemplating suicide are rarely 
forthcoming about these thoughts, and current medical practice relies on patient reporting 
alone to assess risk for suicidal behavior.  
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With no objective measure available, the chance of identifying and helping these 
patients before it is too late becomes a virtually impossible endeavor. In fact, a large 
study recently found that 45% of suicide completers had seen a primary care provider 
within the month before death, and 77% of all suicide completers had contact with a 
primary care provider within a year of death.5 
However, promising new research is uncovering several neurobiological and 
physiological factors that appear to contribute to a suicidal state.4 These factors are vital 
to investigate, as unlike the subjective contributors to suicide, they have the potential to 
be objectively measured and therefore may be the key to accurate suicide prediction. One 
such factor is the dysfunction of the hypothalamic pituitary adrenal (HPA) axis, which 
results in an abnormal physiological stress response due to elevated levels of the stress 
hormone cortisol. Additionally, suicidal patients have an imbalance of serotonin, 
norepinephrine, and dopamine, neurotransmitters that are crucial for mood regulation.4 
Furthermore, anatomical changes take place in a suicidal brain, particularly in the 
prefrontal cortex,6 the area of the brain responsible for personality, behavior, emotion and 
cognition. Finally, suicidal behavior is dictated in part by the victim’s genetic inheritance 
and epigenetic changes.4 Unfortunately, it has not yet been possible to capture these 
factors and cultivate them for practical suicide risk assessment in a clinical setting.  
However, promising new research has identified several genes that appear to be 
expressed differently in suicide completers and subjects with severe SI. Remarkably, 
these genes can be measured via RNA extraction from a sample of blood.7,8 The 
implications of this research are substantial, for if a simple blood draw can aid in the 
 9
prediction of suicide risk, clinicians may have a feasible tool to assist in the prevention of 
millions of horrific deaths. 
Of particular interest is the SAT1 (aka SSAT, SSAT-110,13,14) gene,8 which plays a 
significant role in the regulation of the polyamine stress response (PSR) system. Physical, 
emotional, and hormonal stressors elicit the PSR system, resulting in increased levels of 
various chemical compounds called polyamines. These compounds alter how the brain 
and body react to stress states.9 SAT1 is a protein coding gene located on the x 
chromosome.10 It codes for spermine/spermidine N1-acetyltransferase, the rate limiting 
enzyme in the catabolism of polyamines,10 and thus plays a direct role in controlling the 
PSR system.9 Alterations in SAT1 regulation subsequently result in altered levels of 
spermine and spermidine, potentially disrupting polyamine homeostasis and profoundly 
modifying the body’s response to stress. This may explain, at least in part, one of the 
mechanisms that contributes to a suicidal brain. If this gene is indeed altered in patients 
who commit suicide or have suicidal thoughts, and this gene can be measured with a 
blood test, an intriguing consideration arises: perhaps this gene can be used as a 
biomarker to aid in the prediction of a patient’s predisposition for suicidal behavior. 
METHODS 
An exhaustive search of available medical literature was conducted using 
Medline-OVID, PsychINFO, and Web of Science using the keywords: suicide, SAT1, 
and acetyltransferase. The search was narrowed to include only English language and 
human study articles.  The bibliographies of the articles were further searched for 
relevant sources.  Articles with primary data evaluating the regulation of the SAT1 gene 
in subjects who completed suicide or experienced SI were included. Relevant articles 
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were assessed for quality using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE).11  
RESULTS 
 
The initial result of the search yielded 32 articles for review.  After screening 
relevant articles for English language and human studies, a total of four articles met 
inclusion criteria.  These articles included two cohort studies12,15 and two case control 
studies.13,14  See Table I. 
Discovery and validation of blood markers for suicidality  
 In 2013, Le-Niculescu et al12 published a study in which 4 cohorts were analyzed: 
a live discovery cohort consisting of male patients diagnosed with bipolar disorder, a 
postmortem cohort of suicide completers, a prospective live bipolar cohort, and a 
prospective live psychosis cohort. 
  The primary study group, the live discovery bipolar cohort, consisted of male 
patients previously diagnosed with bipolar disorder. At the initial visit, study psychiatrists 
and researchers independently determined these participants had bipolar disorder using a 
standardized diagnostic assessment. Study participants then returned for two subsequent 
visits, at three and six months post diagnostic evaluation. At these visits, the patient’s 
level of SI was assessed using the Hamilton Rating Scale for Depression (appendix A) 
questionnaire (HRSD-17), and a blood sample was taken. After these two visits, 
researchers compared the HRSD-17 score obtained from the initial visit to the HRSD-17 
score obtained at the follow up visit, and identified those patient’s who had a significant 
increase in SI between the three and six month visits. Nine participants were observed to 
have a marked increase in SI and were thus recognized as the study group.  
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RNA was extracted from the blood samples supplied by these nine patients. Using 
microarray analysis, researchers analyzed gene expression when the patient reported low 
or no SI, and compared these to gene expression when the patient reported high SI.12 
In order to identify those genes associated with SI, whole-genome gene 
expression profiling was conducted. A list of 246 overlapping genes was produced. The 
convergent functional genomics (CGF) approach (appendix B) was then used to prioritize 
each of these genes as a genomic biomarker for suicidality. The SAT1 gene was the top 
scorer of all of the genes analyzed. Using the CFG approach, SAT1 expression was 
significantly increased in the blood samples of all nine patients when they reported high 
SI. These same patients had lower levels of SAT1 expression when no or low SI was 
reported.12 
In an effort to assess whether SAT1 expression relates to completed suicide as 
well as increased SI, researchers then analyzed blood samples taken from nine male 
suicide completers using the same method of gene extraction and comparison as 
described above. Results showed SAT1 gene expression elevation in all nine of the blood 
samples extracted from the suicide victims. Notably, the increase in SAT1 expression 
was at least three standard deviations above the average level of expression in high SI 
subjects,12 suggesting that increasing levels of SAT1 expression result in increasing risk 
for committing suicide. 
To further validate these findings, researchers conducted a prospective study 
examining the rate of subsequent and previous hospitalizations related to suicidal 
behavior in two additional cohorts composed of patients at an increased risk of suicide: a 
live bipolar cohort and a live psychosis cohort. Le-Niculescu et al12 found that those 
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patients with higher SAT1 levels in both groups were more likely to have a future 
hospitalization due to a suicide attempt and were more likely to have a history of these 
hospitalizations. As in the two previous cohorts examined, higher SAT1 levels positively 
correlated with suicidal behavior.12 See Table II. 
Also of particular interest, these researchers assessed the utility of using a 
multidimensional approach, which included the objective marker of SAT1 expression in 
the blood combined with subjective markers provided by patient report, to aid in the 
prediction of future suicide related hospitalization. Using the data obtained from the 
examination of the prospective cohorts, researchers determined that the predictive value 
of SAT1 gene expression elevation was significantly enhanced with the addition of data 
about the patient’s perception of mood, anxiety, and psychosis.12 See Table III. 
Genetic and Epigenetic Analysis of SSAT Gene Dysregulation in Suicidal Behavior  
 This study, conducted by Guipponi et al13 in 2008, aimed to validate previous 
findings that SSAT gene dysregulation plays a role in suicidal behavior,14 while also 
attempting to identify an association between suicidal behavior and certain single 
nucleotide polymorphisms (SNPs), substitutions in a sequence of DNA,16 located on the 
SSAT gene. This case control study was broken down into two distinct parts: a gene 
expression portion, in which researchers aimed to characterize the relationship between 
SSAT dysregulation and suicidal behavior, and a gene association portion, in which 
researchers attempted to identify the basis of SSAT expression.13  
In order to conduct the gene expression portion of the study, researchers extracted 
tissue samples from the brains of 20 (11 M/9 F) suicide completers, some of whom had 
psychiatric diagnoses and others who did not, and compared these to tissue samples taken 
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from the brains of 20 (10 M/9 F) subjects with no history of suicidal behavior or 
psychiatric illness, but had died suddenly of some other cause. The tissue samples were 
extracted from Brodmann’s area 11 in the prefrontal cortex,13 an area of the brain 
associated with suicide.4,13,14  Using quantitative PCR, RNA was extracted from these 
samples and analyzed for gene expression. Results showed a significant decrease in 
SSAT expression in the brain tissue of suicide victims with or without major psychiatric 
diagnoses compared to controls.13 
 Next, researchers performed the gene association portion of the study to examine 
SNPs located within the SSAT gene and identify possible correlations between certain 
SNPs and suicidal behavior. Prior research showed that one SNP in particular, 
rs6526342, appeared to be associated with SSAT expression levels.13,14 To further explore 
this finding, two SNPs were evaluated in this study; rs6526342 and rs17286006, the latter 
chosen for its proximity to rs6526342.13 This portion of the study examined SSAT 
expression and SNP variations in a cohort of 88 suicide completers, and compared these 
findings to a cohort of 449 suicide attempters as well as a control group of 224 subjects.  
Participants in the suicide attempter cohort were recruited from a psychiatric 
hospital after a suicide related admission. RNA was extracted from the blood samples 
taken from these patients and from the brain tissue of the suicide completers. The RNA 
extracted from the blood and brain tissue samples was examined for SSAT gene 
expression, also using quantitative PCR.13 Additionally, researchers examined SSAT 
gene expression levels in blood samples taken from subjects recruited from a blood 
donation center with no history of a suicide attempt and compared SSAT expression in 
these samples to the previous two cohorts. All groups were then genotyped for the 
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rs6526342 and rs17286006 SNPs, and the frequencies of the appearance of these SNPs 
were compared between clinical groups.  Interestingly, even though SSAT levels varied, 
the SNP distributions were no different between the three groups, concluding that these 
particular variations have no effect on suicidal behavior.13 
 Guipponi et al13 validated previous findings of an association between suicide and 
SSAT gene dysregulation. Additionally, this study demonstrated similar results in male 
and female subjects, suggesting that despite being found on the x chromosome,11 the gene 
is not likely sex related.13 This study also examined subjects with and without diagnoses 
of major psychiatric pathologies, and found that the SSAT gene was downregulated in the 
brain tissue of all suicide victims, regardless of diagnosed psychiatric illness. This 
suggests the hypothesis that abnormal expression of the gene may be an independent risk 
factor for suicide, regardless of accompanying psychopathology.  
However, these researchers were not successful in demonstrating an association 
between SNPs located on the SSAT gene and suicidal behavior.  Therefore, the cause of 
SSAT gene dysregulation remains unclear.13 See Table IV. 
Implication of SSAT by Gene Expression and Genetic Variation in Suicide and 
Major Depression 
 This case control study conducted by Sequeira et al14 in 2006 analyzed SSAT 
gene expression in three areas of the brain and compared the findings between three 
groups; 16 suicide completers diagnosed with major depressive disorder (MDD), 18 
suicide completers with no history of MDD, and 12 matched controls with no history of 
suicidal behavior or psychiatric illness who died suddenly by some other cause. 
Researchers selected three cortical brain regions previously implicated in suicide and 
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depression: BA8/9 (the dorsolateral prefrontal cortex),17,18 BA11 (the orbital cortex),17 
and BA4  (the motor cortex).19 Additionally, researchers analyzed the relationship 
between the expression of an allelic variant, SSAT342A/C, and predisposition to 
suicide.14 
Tissues used for analysis were extracted from these three cortical regions. Using 
microarray, semiquantitative RT-PCR, and western blot analysis techniques, decreased 
SSAT gene expression was demonstrated in both suicide completer groups in all three 
brain areas examined compared to controls.14 The decreased expression of SSAT resulted 
in higher levels of spermidine/spermine N1-acetyltransferase,14 the rate limiting enzyme 
in the PSR system,10 in the suicide groups. This finding was especially pronounced in the 
MDD suicide group compared to the non-MDD suicide group, suggesting a possible role 
of SSAT gene dysregulation in the pathophysiology of depression as well as suicide. 
Additionally, the discovery of increased levels of spermidine/spermine N1-
acetyltransferase in the suicide completer group provides additional evidence linking PSR 
system dysfunction to suicidal behavior.14 See Table V.  
Next, researchers examined an allelic variant of interest, SSAT342A/C. The 
authors noted that SSAT expression was significantly affected in subjects with the 
SSAT342A/C allele, observing that patients with the allele had a higher rate of suicide. 
To further explore this connection, researchers genotyped samples from 181 suicide 
completers and 80 controls, specifically checking for this allele. This analysis 
demonstrated a higher frequency of this allelic variant among suicide cases. Subjects 
whose genotype expressed the SSAT342A/C variant were more likely to have committed 
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suicide, while those subjects without the variant were less likely to have died by 
suicide.14   
Profiling Brain Expression of the Spermidine/Spermine N1-Acetyltransferase 1 
(SAT1) Gene in Suicide 
This case control and cohort study conducted in 2008 by Klempan et al15 
endeavored to expand upon the findings discussed by Sequeira et al14 by identifying 
additional brain areas associated with SAT1 gene dysregulation, while attempting to 
validate previous findings associating altered SAT1 expression and a dysfunctional PSR 
system with suicidal behavior. In addition to analyzing 17 new brain regions for SAT1 
expression, the authors also attempted to replicate previous findings of SSAT expression 
abnormalities in suicide victims by investigating genetic expression in a previously 
unexamined sample of suicide completers.15 See Table VI. 
 This study utilized a design similar to Sequeira et al14 and examined three groups: 
a suicide completers group whose subjects had been previously diagnosed with MDD, a 
suicide completers group not diagnosed with MDD, and a control group. The subjects in 
this study represented a cohort that overlapped with the cohort examined by Sequiera et 
al.14 Seventeen areas of the brain were identified and tissue samples from each area were 
collected for analysis. Using microarray and RT-PCR analysis, all but two brain regions 
showed lower levels of SAT1 expression in all suicide completers. Of these, five cortical 
brain regions were statistically significant (ba4, ba11, ba20, ba21, ba44).15 Similar to the 
findings from Sequeira et al,14  down regulation of the SAT1 gene was significantly more 
pronounced in the brain tissue samples of MDD suicide completers than non-MDD 
suicide completers.14,15 
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 Additionally, Klempan et al15 examined levels of SAT1 gene expression in a 
previously unexamined German cohort. Study subjects consisted of a group of five 
suicide completers diagnosed with MDD (3 M/2 F) and 10 non-suicide controls (7 M/3 
F). SAT1 expression was evaluated using tissue samples from two cortical brain regions: 
ba11 and ba17.15 Using the RT-PCR method, both regions demonstrated significantly 
reduced levels of SAT1 expression in depressed individuals who died by suicide.15  
 This study demonstrated SAT1 gene downregulation in the brain tissue of suicide 
completers in at least five out of the 17 cortical brain regions examined.15 These 
researchers concluded that changes in polyamine metabolism, which occurs as a direct 
result of genetic coding, is correlated with suicide completion.15 These findings were 
especially pronounced in patients suffering from MDD.15 Furthermore, this study 
validated previous findings that the SAT1 gene is altered in suicide completers.13,14,15 
DISCUSSION 
Summary of Findings    
These studies12,13,14,15 certainly suggest that errors in SAT1 genetic coding, 
resulting in an imbalance of polyamine levels, plays a key role in suicidality. All four 
studies12,13,14,15 examined in this review successfully identified alterations in SAT1 gene 
expression in suicide completers.  
Furthermore, the discovery of elevated SAT1 gene levels in the blood samples of 
live patients with SI by Le-Niculescu et al12 is particularly encouraging, as this gene may 
indeed act as a biomarker for the prediction of suicide.  These authors also demonstrated 
an intriguing correlation between high SAT1 levels and hospitalizations due to suicidal 
behaviors. Additionally, these researchers confirmed that using a multidimensional 
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approach that includes SAT1 gene expression analysis in combination with subjective 
markers when assessing a patient for SI increases the likelihood of accurately predicting 
future suicide related hospitalizations.12 
Sequeira et al14 exposed and expounded upon the hypothesis that an imbalance of 
PSR enzymes relates to a dysfunctional stress response,9,14 a known factor for increased 
risk of suicide.4 These researchers also identified a genetic variant that appears to be 
connected to suicide, further implicating a genetic component to this behavior.14  
While the research presented is preliminary and significantly limited by study 
design, small sample size and a lack of diversity,12,13,14,15 the results have implications 
furthering the understanding of the pathophysiology of suicide and for the possible 
development of an accurate and practical blood test to track suicidal risk. 
Implications for Clinical Practice 
This research identifies a correlation between SAT1 gene abnormalities and 
suicide. However, research is still in the most preliminary of stages and at this point not 
particularly applicable to clinical practice. Only a correlation between SAT1 gene 
dysregulation and suicide was demonstrated,12,13,14,15 and this correlation does not 
definitively prove that the two are linked. No study has yet explained why these changes 
occur, and it remains unclear if these genetic alterations result in an increased risk of 
suicide, or if a predisposition to suicide results in these alterations. Even if absolute 
causation was identified, no blood test yet exists in a clinical setting that specifically 
examines SAT1 gene expression. 
Furthermore, considering the inherent complexities associated with predicting 
another person’s future behavior, especially regarding something as complex and 
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impulsive20 as suicide, combined with the general challenges of practicing medicine, it is 
highly unlikely that suicide will ever be totally predictable. As previously discussed, 
suicide is the result of several objective and subjective factors. The subjective factors that 
are contributory to a suicidal state cannot be definitively measured. However, the 
implications of this research are still substantial for health care providers.  
Perhaps the most important finding for clinicians working with patients suffering 
from mood disorders is the evidence presented by Le-Niculescu et al12 regarding the 
efficacy of using a multidimensional approach when assessing patients for suicide risk. 
These researchers found that utilizing SAT1 gene expression as part of a 
multidimensional approach greatly increased the likelihood of accurately predicting a 
suicide related hospitalization. In fact, objective measurement of SAT1 gene expression 
in the blood, combined with subjective reports, resulted in 95% accuracy rate for 
predicting future suicide related hospitalizations for patients with high SAT1 expression, 
high levels of anxiety, perceptions of psychosis, and depressed mood.12 While it is 
unlikely that a single questionnaire, blood test, or study will ever predict with total 
confidence something as complex as suicide, these findings suggest that utilizing multiple 
tools and approaches results in a higher likelihood of accurately predicting, and therefore 
preventing, these deaths. 
Likewise, a genetic biomarker may someday be immensely helpful to clinicians 
for use in tracking disease progression and response to therapy, something that is already 
being done with biomarkers for diseases like cancer.21 The clinical implications of this 
are considerable, for if a clinician is able to objectively assess a patient’s baseline suicide 
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risk and then track this patient’s response to therapy, treatment regimens could be vastly 
improved and many lives could be saved.  
Also of essential use for clinicians, especially in these preliminary stages of 
research, is the general awareness this research raises regarding suicide. The lack of 
understanding surrounding suicide and mental health disease is alarming. Many people in 
the general public and healthcare providers alike still consider suicide a selfish personal 
choice, and regard mental health disease as a personal failing and problem that can be 
cured with willpower alone.7 Studies such as these, that link mental illness to 
genetics12,13,14,15 and neurobiological factors,14 provide enlightenment and education for 
people to better understand these diseases. This type of awareness is a key factor in 
reducing stigma and stamping out damaging and uninformed perceptions about suicide. 
These studies, and several like them, are gaining wide attention in the mainstream media, 
bringing awareness to the general public and modifying outdated clinical practice.  
Study Limitations 
The studies, while promising, have major limitations and flaws. Based on the 
GRADE criteria,11 the overall quality of the studies reviewed is very low. The most 
pronounced limitation is design as the studies were either cohort12,15 or case control.13,14 
Therefore, though a correlation was shown between SAT1 gene expression, 
suicide,12,13,14,15 and SI,12 there is no evidence to show that the genetic alterations 
observed in study subjects directly influenced their suicidal behavior. Additionally, there 
is no explanation as to why these changes occur, and while SAT1 dysregulation certainly 
appears to occur in suicidal patients, it is unclear if these alterations cause suicidal 
behavior or if suicidal behavior is a consequence of these alterations.13 Furthermore, all 
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the sample sizes were small and nearly all the participants were white, with a majority 
being male.12,13,14,15  
Because of the postmortem nature of the majority of the studies, concern for 
selection, performance, and attrition bias is low. The outcomes measured in the Guipponi 
et al,13 Sequeira et al,14 and Klempan et al13 studies are definitive and the variables 
examined are not easily manipulated. The Le-Niculescu et al12 study is at a slightly 
higher risk for bias as the study dealt with live cohorts and a peripheral marker, blood 
instead of brain tissue samples, however the risk still remains relatively low as an 
objective factor, SAT1 regulation, was the main outcome examined. 
Also, there is a slight risk for recall bias in the research conducted by Sequeira et 
al.14 The study examined two groups of suicide completers, one group consisted of 
subjects diagnosed with MDD and the other group consisted of subjects not diagnosed 
with MDD. These diagnoses were obtained via interviews with a proxy in a postmortem 
psychological autopsy,14 therefore raising the concern that these diagnoses are not 
accurate.  
Additionally, multiple variations between studies were identified throughout this 
literature review. While these variations are not of great relevance to the conclusions 
presented, it is important to acknowledge and discuss these variations in terms of general 
study limitations. The most conspicuous and essential variation was that Le-Niculescu et 
al12 demonstrated that increased expression of the SAT1 gene is associated with suicide,12 
whereas the other three studies found decreased SAT1 gene expression is associated with 
suicide.13,14,15 Several possible explanations may explain these findings. First, Guipponi 
et al,13 Sequeira et al,14 and Klempan et al15 conducted experiments in which RNA 
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extracted from brain tissue samples was used to evaluate gene expression, while Le-
Niculescu et al12 used peripheral blood cells for RNA extraction to assess gene 
expression. It is certainly possible, and even likely, that gene expression profiles differ 
between brain tissue and blood cells. Therefore, the finding that the SAT1 expression is 
altered depending on the type of cell used for RNA extraction is not necessarily a 
contradictory or even surprising finding. Next, the research presented by Le-Niculescu et 
al12 is 18 months old, whereas the research presented by Guipponi et al13 and Klempan et 
al15 is six years old, and the research published by Sequeira et al14 is eight years old. The 
ability to examine gene expression is relatively new, and significant innovations in this 
field are common. Considering the time lapse between studies, modifications in 
experimentation between study publications may account for these seemingly conflicting 
results. Finally, the studies analyzed in this review all employed different methods for 
RNA quatification.12,,13,14,15 Le-Niculescu et al12 used microarray analysis, Guipponi et 
al13 used quantitative PCR, Sequeira et al14 used microarray analysis, semiquantitative 
RT-PCR, and western blot, and Klempan et al15 used microarray analysis and RT-PCR. 
The divergent findings presented in this review may well be attributed to the differing 
methods of gene expression and profiling used by study authors. (Lisa Sardinia, PhD, JD, 
email communication, December 30, 2014).  
Another variation was that Sequeira et al14 reported identifying an allelic variant 
of the SAT1 gene that appears to increase predisposition to suicide. This finding was not 
replicable by Guipponi et al.13  
Finally, Sequeira et al14 and Klempan et al15 found SSAT expression to be 
markedly altered between suicide completers with MDD and suicide completers without 
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MDD. However, Guipponi et al13 reported that SSAT is downregulated equally across all 
psychopathologies, implying no increased risk for suicide in patients suffering from 
MDD.  
Areas of Future Research 
Several areas for potential research are identified by this review. First, all four 
studies12,13,14,15 implicate the PSR system in suicidal behavior, yet this system is poorly 
understood. The relationship between the genes that control the PSR system and its role 
in suicidal behavior is intriguing, as preliminary research shows that PSR system 
dysfunction contributes significantly to the altered stress reactions implicated in suicide.9 
Therefore, it is important to further investigate why and how this system is controlled and 
what factors contribute to it’s malfunction in a patient suffering from SI. Further research 
exploring how this system operates may contribute significantly to better understanding 
suicidal behavior.  
Another intriguing area for future research is the examination of SAT1 gene 
expression in live subjects in response to therapy. The utility of a biomarker is not only 
its use in tracking risk for a particular disease, but also to gauge effectiveness of therapy 
and response to treatment. It is fundamental to explore the utility of the SAT1 gene in this 
capacity.  
Finally, before the clinical applicability of using the SAT1 gene as a predictor of 
suicide can be determined, these studies need to be replicated in much larger and more 
diverse populations. Researchers must conduct additional studies using standardized 
methods of gene extraction and expression that yield similar results. Also, more studies 
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must be performed examining SAT1 expression in the blood specifically, rather than 
brain tissue.  
CONCLUSION 
 
SAT1 gene regulation is altered in patients who commit suicide and have high SI 
according to the data presented in these studies,12,13,14,15 implicating genetics and the PSR 
system in suicidal behavior. Research is in the most preliminary of stages, and currently 
there is no explanation as to why these defects occur. While the SAT1 gene may indeed 
act as a biomarker for susceptibility to suicidal behavior, no blood test identifying SAT1 
expression currently exists outside of a research setting, so implications for clinical 
practice are minimal. However, with additional research furthering the understanding of 
SAT1 dysregulation in suicide, the potential exists for the development of a blood test 
identifying SAT1 expression abnormalities. This test may someday be a key factor in 
determining suicide risk.  
The successful validation of the SAT1 gene as a biomarker for suicide prediction 
relies on several areas of additional research. First, identifying the role the PSR system 
plays in genetics and the role genetics play in the PSR system is fundamental not only to 
the development of an accurate and reliable blood test for suicide prediction, but also in 
understanding suicidal behavior. Second, examining the fluctuations of SAT1 gene 
expression in live patients in response to therapy will be the next step in developing these 
blood markers for clinical applicability. Finally, these studies need to be replicated using 
standardized methods in larger and more diverse patient populations.  
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Table I. Characteristics of Reviewed Studies 
 
Quality Assessment  
 Downgrade Criteria  Quality 
Study Design Limitations Inconsistency Indirectness Imprecision 
 
Publication 
bias 
Mortality (Suicide) 
Le-
Niculescu 
et al12 
Cohort Not serious  Not serious  Not seriousa Serious b None likely Very 
Low 
Guipponi 
et al13 
Case 
Control 
Not serious Not serious Not serious Seriousc None likely Very 
Low 
Sequeira 
et al14 
Case 
Control 
Seriousd Not serious  Not serious Seriouse None likely Very 
Low 
Klempan 
et al15 
Cohort Seriousf Not serious  Not serious Seriousg None likely Very 
Low 
Suicidal Ideation  
Le-
Niculescu 
et al12 
Cohort Not serious  Not serious  Not serious  Seriousb None likely Very 
Low 
Suicide related hospitalization 
Le-
Niculescu 
et al12 
Cohort Not serious  Not serious  Not serious  Serioush  None likely Very 
Low 
aBlood samples were used as biomarkers to measure SAT1 expression 
bThe sample size is small (n=9) 
cThe sample size is small (n=20) 
dConcern for recall bias: one study group includes non-depressed suicide completers and the other includes depressed 
suicide completers. These diagnoses were obtained postmortem via psychological autopsy, therefore relied upon by 
interviews with a proxy resulting in high risk of recall bias 
eThe sample size is small (n=24) 
fNo statistical analysis provided regarding SAT1 expression in the control group compared to the sample group 
gThe sample size is small (n=5) 
hThe sample size is small (n=42 prospective bipolar group/n=46 prospective psychosis group)
 28
Table II – VI. Summary of Findings 
 
Table II. 
Le-Niculescu et al12 
Study group SSAT mean expression P value Quality Importance 
Suicide Completers 
n=8 
7171.51 0.0057 Very Low Critical 
High Suicidal Ideation 
n=9 
3214.37 0.0057 
No Suicidal Ideation 
n=9 
2642.97 0.0057 
 
Table III. 
Le-Niculescu et al12 
 95% CI 
Number of 
Dimensions 
Test Result Variable Area 
Under 
Curve 
Standard 
Deviation 
Error 
Significance Low High 
1D SAT1 0.640 0.086 0.224 .471 .808 
2D SAT1+anxiety 0.798 0.068 0.009 .665 .931 
3D SAT1+anxiety+mood 0.813 0.066 0.006 .683 .942 
4D SAT1+anxiety+mood+psychosis 0.835 0.066 0.004 .706 .964 
 
Table IV. 
Guipponi et al13 
Study Groups SSAT Expression P-value Quality Importance 
Suicide completers 
n=20 
-0.497 ± 0.11 0.007 Very Low Critical 
Control group 
n=20 
0.0721±0.15 
 
Table V.  
Sequeira et al14 
Suicide Completer (MDD) 
n=16 
Suicide Completer 
(No MDD) 
n=8 
Control 
n=12 
P value Importance 
Brain Area Relative 
SSAT 
expression 
Brain Area Relative 
SSAT 
expression 
Brain Area Relative 
SSAT 
expression 
Critical  
BA4 FC: -1.6 BA4 FC: -1.6 BA4 FC: -1.4 P<.001 
BA8/9 FC:-1.4 BA8/9  BA8/9 FC: -1.4 P<.05 
BA11 FC: -1.8 BA11 FC: -1.8 BA11 FC: -1.4 P<.001 
Abbreviations: MDD, major depressive disorder; FC, fold change; BA, Brodmann area 
 
Table VI. 
Klempan et al15 
Depressed 
Suicide Completers 
n=5 
Controls 
n=10 
P value Importance 
Brain area SSAT 
Expression 
Brain area SSAT 
Expression 
Critical 
BA11 FC:-1.5 BA11  P=0.05 
BA17 FC:-1.6 BA17  P=0.05 
Abbreviations: FC, fold change; BA, Brodmann area  
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Appendix A 
The Hamilton Depression Rating Scale 1722 
 
Appendix B 
Convergent Functional Genomics
Biomarkers12  
 
Bipolar Subjects
Whole Blood 
Differentially 
Expressed in no SI 
vs. High SI
(6 points)
 Model For Identification and Prioritization of Suicide 
Candidate 
Gene
Biomarker
Human Postmortem 
Brain Evidence 
(4 points)
Human Genetic 
Evidence-
association, CNV, or 
linkage
(2 points)
 
